Bioethics News

The Drug Company That Shocked the World with Its Prices Dodged $10 Billion in Taxes, Report Says

July 13, 2016

(The Washington Post) – Over the last few years, Gilead Sciences has grown into one of the world’s largest pharmaceutical companies, fueled by the sales of expensive specialty treatments for hepatitis C. The company’s revenue has tripled since 2012, to $32.6 billion last year. According to a report to be released Wednesday, Gilead has also developed another specialty: Avoiding billions in taxes.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.